Skip to main content
NCBI home page
British Medical Journal (Clinical Research Ed.) logoLink to British Medical Journal (Clinical Research Ed.)
. 1981 Mar 7;282(6266):771–773. doi: 10.1136/bmj.282.6266.771

Patient-controlled dose regimen of methadone for chronic cancer pain.

J Säwe, J Hansen, C Ginman, P Hartvig, P A Jakobsson, M I Nilsson, A Rane, E Anggård
PMCID: PMC1504645  PMID: 6163497

Abstract

Fourteen patients with severe cancer pain participated in a trial of methadone given in a fixed dose (10 mg) but at intervals selected by the patients themselves during the loading phase. The aim was to achieve rapid pain relief while avoiding the risk of toxicity from accumulation of methadone. As expected, the dosage intervals increased gradually over the first few days of treatment, the daily dose decreasing from 30-80 mg on the first day to 10-40 mg at the end of the week. Plasma concentrations of methadone varied sevenfold after four to five days (0.24 to 1.75 mumol/1; 7.4 to 54.2 microgram/100 ml). Eleven patients reported complete or almost complete pain relief and elected to continue with methadone after the study. In no case was treatment withdrawn because of intoxication. From these findings a patient-controlled dosage regimen of oral methadone may be an effective and safe alternative to parenteral narcotic medication, adjusting both for individual variation in pain intensity and for pharmacokinetics.

Full text

PDF
771

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Anggård E., Nilsson M. I., Holmstrand J., Gunne L. M. Pharmacokinetics of methadone during maintenance therapy: pulse labeling with deuterated methadone in the steady state. Eur J Clin Pharmacol. 1979 Aug;16(1):53–57. doi: 10.1007/BF00644967. [DOI] [PubMed] [Google Scholar]
  2. Beaver W. T., Wallenstein S. L., Houde R. W., Rogers A. A clinical comparison of the analgesic effects of methadone and morphine administered intramuscularly, and of orally and parenterally administered methadone. Clin Pharmacol Ther. 1967 May-Jun;8(3):415–426. doi: 10.1002/cpt196783415. [DOI] [PubMed] [Google Scholar]
  3. Berkowitz B. A. The relationship of pharmacokinetics to pharmacological activity: morphine, methadone and naloxone. Clin Pharmacokinet. 1976;1(3):219–230. doi: 10.2165/00003088-197601030-00004. [DOI] [PubMed] [Google Scholar]
  4. Ettinger D. S., Vitale P. J., Trump D. L. Important clinical pharmacologic considerations in the use of methadone in cancer patients. Cancer Treat Rep. 1979 Mar;63(3):457–459. [PubMed] [Google Scholar]
  5. Inturrisi C. E., Verebely K. Disposition of methadone in man after a single oral dose. Clin Pharmacol Ther. 1972 Nov-Dec;13(6):923–930. doi: 10.1002/cpt1972136923. [DOI] [PubMed] [Google Scholar]
  6. Olsen G. D., Wendel H. A., Livermore J. D., Leger R. M., Lynn R. K., Gerber N. Clinical effects and pharmacokinetics of racemic methadone and its optical isomers. Clin Pharmacol Ther. 1977 Feb;21(2):147–157. doi: 10.1002/cpt1977212147. [DOI] [PubMed] [Google Scholar]
  7. Symonds P. Methadone and the elderly. Br Med J. 1977 Feb 19;1(6059):512–512. doi: 10.1136/bmj.1.6059.512. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Tamsen A., Hartvig P., Dahlström B., Lindström B., Holmdahl M. H. Patient controlled analgesic therapy in the early postoperative period. Acta Anaesthesiol Scand. 1979 Oct;23(5):462–470. doi: 10.1111/j.1399-6576.1979.tb01475.x. [DOI] [PubMed] [Google Scholar]
  9. Valentine A. S., Steckel S., Weintraub M. Pain relief for cancer patients. Am J Nurs. 1978 Dec;78(12):2054–2056. [PubMed] [Google Scholar]

Articles from British Medical Journal (Clinical research ed.) are provided here courtesy of BMJ Publishing Group

RESOURCES